Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stimulate the immune system in different ways and stop tumor cells from growing.

PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib in treating patients with stage IIIB or stage IV non-small cell lung cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jonsson Comprehensive Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Celecoxib; Cyclooxygenase 2 Inhibitors

Criteria

Inclusion Criteria:

• Histologically confirmed non-small cell lung cancer

• Stage IIIB or IV disease

• Radiographically measurable disease

• 18 and over

• Performance status: ECOG 0-2

• Renal: Creatinine ≤ 2 mg/dL

• Negative pregnancy test

• Fertile patients must use effective contraception

• More than 4 weeks since prior chemotherapy

• Endocrine therapy: More than 4 weeks since prior corticosteroids; No concurrent corticosteroids, including chronic corticosteroids, except for medically-indicated topical steroids

• Radiotherapy: More than 4 weeks since prior radiotherapy

• More than 4 weeks since other prior anticancer therapy

• More than 4 weeks since prior non-cytotoxic investigational agents

• At least 72 hours since prior nonsteroidal anti-inflammatory drugs (NSAIDs)

Exclusion Criteria:

• pregnant or nursing

• comorbid disease, psychiatric condition, chronic medical condition, or laboratory abnormality that would preclude study treatment or compliance with study requirements

• hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study reagent

• history of gastrointestinal ulceration, bleeding, or perforation

• other concurrent cyclooxygenase-2 or -3 inhibitors

• other concurrent NSAIDs